Dana-Farber Cancer Institute
dana-farber.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
820
Active
229
Phase 3
17
Total enrollment
326,872
Pipeline matrix
Showing 40 of 170 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prednisone | — | — | 16 | ||||
| Everolimus | — | — | — | 10 | |||
| Sirolimus | — | — | — | 10 | |||
| Cosibelimab | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | 33 | |||
| Dexamethasone | — | — | 24 | ||||
| Methotrexate | — | — | — | 20 | |||
| Cytarabine | — | — | — | 11 | |||
| Bortezomib | — | — | 23 | ||||
| Doxorubicin | — | — | 15 | ||||
| Etoposide | — | — | — | 14 | |||
| Vincristine | — | — | — | 10 | |||
| Melphalan | — | — | — | 4 | |||
| mercaptopurine | — | — | — | — | 3 | ||
| Isatuximab | — | — | — | — | 2 | ||
| Iberdomide | — | — | — | — | 2 | ||
| leucovorin calcium | — | — | — | 5 | |||
| Dexrazoxane | — | — | — | — | 3 | ||
| hydrocortisone | — | — | — | — | 3 | ||
| pegaspargase | — | — | — | — | — | 2 | |
| Dasatinib | — | — | — | — | 2 | ||
| Erwinia asparaginase | — | — | — | — | — | 1 | |
| NELARABINE | — | — | — | — | — | 1 | |
| Linvoseltamab | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 29 | ||
| Venetoclax | — | — | — | — | 14 | ||
| Nivolumab | — | — | — | — | 22 | ||
| Ipilimumab | — | — | — | — | 13 | ||
| Paclitaxel | — | — | — | 20 | |||
| Rituximab | — | — | — | 23 | |||
| Fludarabine | — | — | — | — | 11 | ||
| Abemaciclib | — | — | — | — | 10 | ||
| Interleukin-2 | — | — | — | 9 | |||
| Ibrutinib | — | — | — | — | 9 | ||
| Carboplatin | — | — | — | 19 | |||
| Letrozole | — | — | — | — | — | 8 | |
| Pertuzumab | — | — | — | — | 6 | ||
| Sacituzumab Govitecan | — | — | — | — | — | 4 | |
| Trastuzumab | — | — | — | 16 | |||
| Olaparib | — | — | — | — | 5 |
130 more active programs hidden
Next readouts
- 2009-07
- 2014-10
- 2017-08
- 2017-09-01
- 2017-10
- 2018-02
- 2018-06
- 2019-07
- 2020-01
- 2020-03
Top conditions
- Breast Cancer118
- Prostate Cancer53
- Ovarian Cancer31
- Multiple Myeloma25
- Leukemia21
- Lung Cancer21
- Cancer21
- Head and Neck Cancer19
Frequently asked questions about Dana-Farber Cancer Institute
- How many clinical trials does Dana-Farber Cancer Institute have on ClinicalTrials.gov?
- Dana-Farber Cancer Institute is listed as the lead sponsor on 820 clinical trials in ClinicalTrials.gov, 229 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Dana-Farber Cancer Institute's trials are in Phase 3?
- 17 of Dana-Farber Cancer Institute's trials are in Phase 3, spread across 170 active drug programs.
- What therapeutic areas does Dana-Farber Cancer Institute focus on?
- Dana-Farber Cancer Institute's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Ovarian Cancer, Multiple Myeloma, Leukemia.
- When are Dana-Farber Cancer Institute's next clinical trial readouts?
- Dana-Farber Cancer Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma”, expected around 2009-07.